Launch six Alvotech biosimilar products in Israel
Deadline passed; outcome being checked
- Announced
- 13 Jan 2021
- Due
- 31 Dec 2025
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the six Alvotech biosimilar products, which, subject to approval by the EMA and subsequently by the IMOH, are expected to be launched between 2022 and 2025”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- six Alvotech biosimilar products
- Where
- Israel
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to approval by the EMA and subsequently by the IMOH
- Depends on
- Regulatory
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Kamada Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KMDA-022011 · Corrections policy